Clarifying information regarding trading stop in Aerocrine AB (publ)
SOLNA, Sweden – September 1 2011 – Aerocrine AB (OMX Nordic Exchange: AERO) today announced that trading in the Company's shares was halted in response to speculation regarding the publication of U.S. guidelines regarding the Company's method.
The company wants to clarify that no official publication of the expected U.S.guidelines regarding inflammation monitoring has been made by the ATS (American Thoracic Society).
Aerocrine will during Friday morning publish a press release with more information.
For more information, please contact:
Paul de Potocki, CEO, tele: +46 8 629 07 80
Michael Colerus, CFO tele +46 8 629 07 85
About Aerocrine Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007. Aerocrine discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 09:45 a.m. on September 1st 2011.